NFL BIOSCIENCES: PATENT APPLICATION FILED IN THE UNITED STATES FOR REDUCING ALCOHOL CONSUMPTION WITH NFL-301 & PREPARATION OF A PRE-IND APPLICATION SUBMISSION WITH THE FDA NFL BIOSCIENCES...
NFL BIOSCIENCES: CO-FOUNDER SHAREHOLDER FURTHER STRENGTHENS HIS POSITION BY EXERCISING “BSPCE” WARRANTS NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company...
NFL BIOSCIENCES: GB HOLDING TAKES A STAKE IN THE COMPANY™S CAPITAL UPON THE EXERCISE OF SHARE SUBSCRIPTION WARRANTS AND PAYMENT OF 0.5M‚¬, AND ALSO COMMITS TO A LOCK-UP NFL BIOSCIENCES (Euronext...
NFL BIOSCIENCES : RESULTS OF THE COMBINED GENERAL MEETING OF JUNE 27, 2023 Appointment of a new director satisfying the independence criteria of the Middlenext Code NFL BIOSCIENCES (Euronext Growth...
NFL BIOSCIENCES: Approval for its patent to be granted on NFL-101 in Europe and approval of the clinical development plan for NFL-101 by the EMA NFL BIOSCIENCES (Euronext Growth Paris “ FR0014003XT0...
NFL Biosciences: Recruitment completed for the PRECESTO study
NFL Biosciences: 2022 full-year business and earnings update
NFL Biosciences : Activités & Résultats annuels 2022
Changes in the governance of NFL Biosciences
NFL BIOSCIENCES: Inclusion of the first volunteer in the PRECESTO study